UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 207

Sortiert nach

A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction

Investigational new drugs, 2011-10, Vol.29 (5), p.1029-1037

2011

Link zum Volltext

Verfügbarkeit prüfen

Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors

Clinical cancer research, 2009-01, Vol.15 (2), p.723-730

2009

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma

Investigational new drugs, 2020-10, Vol.38 (5), p.1448-1453

2020

Link zum Volltext

Verfügbarkeit prüfen

A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer

Clinical cancer research, 2006-10, Vol.12 (19), p.5755-5763

2006

Link zum Volltext

Verfügbarkeit prüfen

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

Clinical cancer research, 2009-06, Vol.15 (12), p.4207-4212

2009

Link zum Volltext

Verfügbarkeit prüfen

Vascular Endothelial Growth Factor Receptor-1 in Human Cancer: Concise Review and Rationale for Development of IMC-18F1 (Human Antibody Targeting Vascular Endothelial Growth Factor Receptor-1)

Cancer, 2010-02, Vol.116 (4), p.1027-1032

2010

Link zum Volltext

Verfügbarkeit prüfen

Lately, it occurs to me what a long, strange trip it's been for the farnesyltransferase inhibitors

Journal of clinical oncology, 2006-07, Vol.24 (19), p.2981-2984

Rowinsky, Eric K

2006

Link zum Volltext

Verfügbarkeit prüfen

Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors

Clinical cancer research, 2008-10, Vol.14 (20), p.6663-6673

2008

Link zum Volltext

Verfügbarkeit prüfen

SL‐401 and SL‐501, targeted therapeutics directed at the interleukin‐3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia

British journal of haematology, 2014-09, Vol.166 (6), p.862-874

2014

Link zum Volltext

Verfügbarkeit prüfen

Polymorphisms in Cyclooxygenase-2 and Epidermal Growth Factor Receptor Are Associated with Progression-Free Survival Independent of K-ras in Metastatic Colorectal Cancer Patients Treated with Single-Agent Cetuximab

Clinical cancer research, 2008-12, Vol.14 (23), p.7884-7895

2008

Link zum Volltext

Verfügbarkeit prüfen

A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies

Clinical cancer research, 2010-03, Vol.16 (6), p.1915-1923

2010

Link zum Volltext

Verfügbarkeit prüfen

Safety, pharmacokinetics, and pharmacodynamics in healthy Chinese volunteers treated with SC0062, a highly selective endothelin‐A receptor antagonist

Clinical and translational science, 2024-03, Vol.17 (3), p.e13750-n/a

2024

Link zum Volltext

Verfügbarkeit prüfen

Rationale for the development of IMC‐3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet‐derived growth factor receptor α

Cancer, 2010-02, Vol.116 (S4), p.1018-1026

2010

Link zum Volltext

Verfügbarkeit prüfen

mTOR Inhibition for Cancer Therapy: Past, Present and Future

1st ed. 2016, 2015

Link zum Volltext

Verfügbarkeit prüfen

A Phase I and Pharmacokinetic Study of Lapatinib in Combination with Letrozole in Patients with Advanced Cancer

Clinical cancer research, 2008-07, Vol.14 (14), p.4484-4490

2008

Link zum Volltext

Verfügbarkeit prüfen

Paclitaxel (Taxol)

The New England journal of medicine, 1995-04, Vol.332 (15), p.1004-1014

1995

Link zum Volltext

Verfügbarkeit prüfen

A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma

Investigational new drugs, 2012-08, Vol.30 (4), p.1597-1606

2012

Link zum Volltext

Verfügbarkeit prüfen

A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer

Clinical cancer research, 2005-05, Vol.11 (10), p.3854-3861

2005

Link zum Volltext

Verfügbarkeit prüfen

Phase I Study of E7820, an Oral Inhibitor of Integrin α-2 Expression with Antiangiogenic Properties, in Patients with Advanced Malignancies

Clinical cancer research, 2011, Vol.17 (1), p.193-200

2011

Link zum Volltext

Verfügbarkeit prüfen

Pharmacodynamic Evaluation of the Epidermal Growth Factor Receptor Inhibitor OSI-774 in Human Epidermis of Cancer Patients

Clinical cancer research, 2003-07, Vol.9 (7), p.2478-2486

2003

Link zum Volltext

Verfügbarkeit prüfen

Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour Infusion Weekly in Patients with Advanced Solid Malignancies

Clinical cancer research, 2009-05, Vol.15 (10), p.3591-3599

2009

Link zum Volltext

Verfügbarkeit prüfen

Targeting FMS‐related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC‐EB10

Cancer, 2010-02, Vol.116 (S4), p.1013-1017

2010

Link zum Volltext

Verfügbarkeit prüfen

Phase I and Pharmacokinetic Study of Pemetrexed with High-Dose Folic Acid Supplementation or Multivitamin Supplementation in Patients with Locally Advanced or Metastatic Cancer

Clinical cancer research, 2007-05, Vol.13 (9), p.2675-2683

2007

Link zum Volltext

Verfügbarkeit prüfen

Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer

Investigational new drugs, 2010-06, Vol.28 (3), p.334-342

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 207

Suche als RSS-Feed

Aktive Filter

KollektionIngenta

SpracheJapanisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(190)
Mit Volltextzugriff
(201)

Publikationsform

Sprache

Englisch
(207)

Erscheinungsjahr

n.n

Thema

Humans
(124)
Oncology
(113)
Life Sciences & Biomedicine
(105)
Science & Technology
(105)
Biological And Medical Sciences
(94)
Medical Sciences
(94)
Antineoplastic Agents
(90)
Pharmacology. Drug Treatments
(89)
Female
(76)
Male
(74)
Middle Aged
(74)
Adult
(71)
Aged
(71)
Neoplasms - Drug Therapy
(59)
Chemotherapy
(56)
Dose-Response Relationship, Drug
(43)
Antineoplastic Agents - Therapeutic Use
(35)
Drug Administration Schedule
(31)
Tumors
(29)
Treatment Outcome
(26)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Clinical Cancer Research
(62)
Cancer Research
(21)
Blood
(17)
Investigational New Drugs
(17)
Journal Of Clinical Oncology
(13)
Jnci : Journal Of The National Cancer Institute
(11)
Cancer
(6)
Oncology
(5)
The New England Journal Of Medicine
(4)
The Oncologist
(3)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction

Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors

Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma

A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells

Vascular Endothelial Growth Factor Receptor-1 in Human Cancer: Concise Review and Rationale for Development of IMC-18F1 (Human Antibody Targeting Vascular Endothelial Growth Factor Receptor-1)

Lately, it occurs to me what a long, strange trip it's been for the farnesyltransferase inhibitors

Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors

SL‐401 and SL‐501, targeted therapeutics directed at the interleukin‐3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia

Polymorphisms in Cyclooxygenase-2 and Epidermal Growth Factor Receptor Are Associated with Progression-Free Survival Independent of K-ras in Metastatic Colorectal Cancer Patients Treated with Single-Agent Cetuximab

A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies

Safety, pharmacokinetics, and pharmacodynamics in healthy Chinese volunteers treated with SC0062, a highly selective endothelin‐A receptor antagonist

Rationale for the development of IMC‐3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet‐derived growth factor receptor α

mTOR Inhibition for Cancer Therapy: Past, Present and Future

A Phase I and Pharmacokinetic Study of Lapatinib in Combination with Letrozole in Patients with Advanced Cancer

Paclitaxel (Taxol)

A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma

A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer

Phase I Study of E7820, an Oral Inhibitor of Integrin α-2 Expression with Antiangiogenic Properties, in Patients with Advanced Malignancies

Pharmacodynamic Evaluation of the Epidermal Growth Factor Receptor Inhibitor OSI-774 in Human Epidermis of Cancer Patients

Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour Infusion Weekly in Patients with Advanced Solid Malignancies

Targeting FMS‐related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC‐EB10

Phase I and Pharmacokinetic Study of Pemetrexed with High-Dose Folic Acid Supplementation or Multivitamin Supplementation in Patients with Locally Advanced or Metastatic Cancer

Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer

Aktive Filter

Suchergebnisse filtern